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Clinical outcome of three fractionation 
schedules of preoperative radiotherapy 
for rectal cancer
Iwona WZIĘTEK, Jerzy WYDMAŃSKI, Rafal SUWIŃSKI
SUMMARY
AIM: To evaluate the effectiveness and normal tissue reactions of three fractionation schedules of 
preoperative radiotherapy for locally advanced rectal cancer.
MATERIALS AND METHODS: Between 1996 and 2002, 168 patients with locally advanced rectal can-
cer were treated as follows: 53 patients received 25 Gy in 5 Gy per fraction (group A), 45 received 30 
Gy in 3.0 Gy per fraction (group B), and 70 were treated with accelerated hyperfractionation: 42 Gy, 
1.5 Gy per fraction, given twice a day with an inter-fraction interval of 6 hours (group C). The clinical 
characteristics of the groups were comparable. The patients did not receive concurrent chemotherapy. 
A Cox proportional hazard regression model was used to analyze the factors which may infl uence 
loco-regional tumour control (LRC) and overall survival (OS). 
RESULTS: The following variables signifi cantly infl uenced LRC: fractionation scheme (5-year LRC 80%, 
69%, and 90% in groups A, B, C respectively, p=0.016), haemoglobin concentration before radio-
therapy (p= 0.012) and postoperative chemotherapy (p=0.01). Age, sex, stage of disease, location of 
tumour (distance of the tumour from the anal verge) and performance status did not appear signifi -
cant for LRC. The overall 5-year OS was 64%, 59% and 74% in groups A, B, C respectively (p=0.056). 
The OS was signifi cantly infl uenced by postoperative pathological stage (p=0.006), tumour location 
(p= 0.015) and postoperative chemotherapy (p=0.047). The most frequent acute radiation reaction 
was mild/severe diarrhoea, which appeared in 5%, 21.6% and 65.5% of the patients from groups A-C 
respectively. The median wound healing time in those who underwent abdomino-perineal resections 
was 6, 6 and 4 weeks. Other reactions appeared less relevant. There was no signifi cant difference in 
the incidence of late effects among the three treatment groups.
CONCLUSION: While due to the non-randomized character of the study the conclusions should be 
regarded as hypothesis-generating only, the analysis has shown an acceptable local effectiveness and 
tolerance of schedules A and C, and disappointing effectiveness of schedule B. The present study thus 
supports the data which suggest that the clinical effect of preoperative radiotherapy for rectal cancer 
is infl uenced not only by total radiation dose but also by overall radiation treatment time and dose 
per fraction.
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BACKGROUND
For several decades surgical resection of the 
primary and of the regional lymph nodes was 
the standard treatment for patients with rec-
tal cancer. Recurrence following surgery has 
been, however, a major problem and was often 
the ultimate cause of death. An improvement 
in surgical technique allows the local recur-
rence rate to be decreased with surgery alone, 
although the reported incidence of 10–30 per-
cent is still not satisfactory [1–4]. The next step 
to reduce local relapse rate and improve over-
all survival was combining surgery with other 
modalities. The value of adding radiotherapy 
to surgery has been assessed in trials using ei-
ther preoperative or postoperative irradiation 
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[5, 6]. The potential advantage of postopera-
tive irradiation is selection of patients based 
on pathological results and the ability to ex-
clude patients who have metastatic disease at 
surgery. The main rationale for introducing 
preoperative irradiation is to sterilize the cells 
that have formed micrometastases around the 
primary tumour or have invaded the nearby 
organs. The outcomes of clinical trials suggest 
a benefi t from preoperative treatment [5–11]. 
However, a large number of issues related to 
total radiation dose and dose per fraction still 
need to be resolved or further refi ned. A great 
number of diverse schedules is used in preop-
erative radiotherapy for locally advanced rec-
tal cancer; these include hypofractionation, 
conventional fractionation and accelerated 
hyperfractionation [12–16]. In this study we 
focused on assessment of the effectiveness 
and acute and late toxicity of three different 
fractionation schedules.
AIM
To evaluate the effectiveness and normal tis-
sue reactions of three fractionation schedules 
of preoperative radiotherapy for locally ad-
vanced rectal cancer. The evaluation of nor-
mal tissue reactions included an analysis of 
the incidence of surgical complications, as 
well as acute and late radiation effects.
MATERIALS AND METHODS
Between February 1996 and May 2002, 168 
patients with locally advanced and histologi-
cally proven rectal cancer were treated at the 
Centre of Oncology, Maria Sklodowska-Curie 
Memorial Institute (Gliwice, Poland). All pa-
tients received preoperative external beam 
radiation to the primary tumour, adjacent 
lymph nodes and presacral region, followed by 
surgery. If the pathological stage was classi-
fi ed as Astler-Coller C, postoperative adjuvant 
chemotherapy was recommended. All patients 
had performance status 0–2 (Zubrod scale) 
with median age of 62 years (21–79 years). 
Prior to initiation of the treatment, all patients 
underwent a complete clinical examination 
and laboratory tests (blood count, renal and 
liver function tests, and CEA). Distant metas-
tases were excluded by chest X-ray, abdomi-
nal ultrasound or computed tomography (CT 
scan). Assessment of the local extent of the 
tumour was evaluated by digital examination, 
rectal ultrasound and/or CT scan. The clinical 
characteristics of the groups were comparable 
and are summarized in Table 1.
Treatment regimens
The fractionation schemes were diversifi ed in 
a non-randomized fashion into three sched-
ules:
A) 53 patients (31%) received 25 Gy in 5 Gy 
per fraction
B) 45 patients (27%) received 30 Gy in 3 Gy 
per fraction
C) 70 patients (42%) were treated with acceler-
ated hyperfractionation: 42 Gy, 1.5 Gy per 
fraction, twice a day with an inter-fraction 
interval of 6 hours
The details of selection criteria for a given 
fractionation schedule have been presented 
elsewhere [17]. Most of the patients in group 
A were admitted as inpatients for surgery 
before the start of radiation, whereas the pa-
tients treated with 30 Gy or 42 Gy attended 
radiation treatment as outpatients from home. 
Additionally, 18 patients from group C (10% of 
all patients) received prophylactic liver irra-
diation – 14 Gy, 1.4 Gy/fx. 
Radiation therapy techniques
Between 1996 and 1998, 15 patients (9%) were 
treated with g-photons using a cobalt machine 
(Siemens, Philips); all other patients under-
went RT with 6–23-MV photons generated by 
a linear accelerator. According to the groups, 
83% vs. 98 % and 93% of patients for groups 
A, B and C respectively were treated with 3D 
technique; the others had 2D treatment plan-
ning. Three-dimensional (3D) three-fi eld (one 
posterior and two lateral fi elds) conformal 
planning technique in all cases was based on 
computed tomography. Patients were placed 
in a supine position and precise and reproduc-
ible patient immobilization was achieved with 
a thermoplastic mask system. Clinical target 
volume included the primary tumour with 
at least a 3 cm margin and internal iliac and 
presacral nodes. The lumbosacral plexus was 
shielded. The prescribed dose was specifi ed 
according to the guidelines of the International 
Commission on Radiation Units Report 50 and 
62, such that the reference point located at the 
centre of the planning target volume received 
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the prescribed dose, and the maximum ac-
ceptable dose inhomogeneity within the clini-
cal target volume was 5%. Portal vision and in 
vivo dosimetry were used to control the refer-
ral points and the dosimetric parameters.
Surgery
The median delay between radiotherapy and 
surgery was 6 days and was slightly shorter 
in group A (3 days) compared with groups B 
and C (9 and 6 days, respectively). Techniques 
of surgery were not standardized in all pa-
tients; however, total mesorectal excision was 
performed in all cases. Detailed information 
about the type of resection and radiothera-
py-surgery interval is shown in Table 2. Be-
cause the patients with rectal cancer in the 
lower portion were considered candidates for 
a sphincter-preservation trial [18], the pro-
portion of patients who underwent anterior 
resection was slightly lower in group A than 
in groups B and C. The differences in hospi-
tal admission practice may refl ect the differ-
ence in median delay between radiotherapy 
and surgery. However, there was no evidence 
in the medical records of any obvious differ-
ences in surgical procedures between groups.
Postoperative chemotherapy
Overall, 75 patients (44.6%) received postop-
erative adjuvant chemotherapy. In general 
postoperative chemotherapy was recommend-
ed for patients with Astler-Coller C stage. The 
regimen was bolus 5-fl uorouracil (425 mg/m2 
for 5 consecutive days) and leucovorin (20 mg/
m2 for 5 consecutive days) every 4 weeks for 
six courses.
Evaluation of acute and late toxicities
During the preoperative treatment, patients 
were seen once a week for a clinical examina-
tion. Toxicity was scored at each visit accord-
ing to the Dishe scale. 
The evaluation of normal tissue early re-
actions also included an analysis of perineal 
wound healing time and morbidity in the peri-
operative period. Late toxicity was evaluated 
according to the RTOG/EORTC scale.
Endpoints and statistical analysis
Loco-regional control was calculated from 
the start of radiotherapy to the time when 
clinical recurrence was detected in the pel-
vis. Failures were defi ned as morphological 
evidence of tumour regrowth. When local re-
currence and distant metastases occurred in 
the same patient, both types of failures were 
recorded, regardless of their sequence. Sur-
vival was calculated from the start of radio-
therapy until the time of death from any cause 
or, in patients who are alive, until the time of 
the last follow-up. The patients were followed 
up at 3-month intervals for the fi rst year, and 
every 6 months thereafter. Each evaluation 
included clinical examination, Zubrod per-
formance status, liver function tests and CEA 
level. Ultrasonography of the liver and chest 
X-ray were performed one year after surgery 
or when indicated in symptomatic cases. Ka-
plan-Meier method was used to plot survival 
curves. To compare survival curves the chi-
square statistic was used. In order to check if 
signifi cant prognostic factors of survival exist, 
the Cox proportional hazard regression model 
was used. The signifi cance of the Cox model 
was checked by chi-square test and the signifi -
cance of parameters used in the Cox propor-
tional hazard regression model was analyzed 
by Wald’s statistic.  All the statistical calcula-
tions were performed with STATISTICA (ver-
sion 6.0). The difference was considered sig-
nifi cant if the p value was less than 0.05.
RESULTS
Acute toxicity
The evaluation of normal tissue reactions in-
cluded an analysis of the incidence of surgi-
cal complications, as well as of acute radiation 
effects. Acute toxicity was assessed using a 
modifi ed Dishe scoring system (19). In 85.7% 
of patients from group A, 57.9% from group 
B and 14.3% from group C no acute reactions 
during radiotherapy were reported. Mild 
acute reactions occurred in 14.3%, 31.6% and 
39.7% of the patients from groups A-C (Dishe 
score below 6 points); moderate reactions 
occurred in 0%, 7.9% and 33.3% % of the pa-
tients from groups A-C (Dishe score between 
6 and 10 points); and severe reactions were 
noticed in 0%, 2.6% and 12.7% of the patients 
from groups A-C (Dishe score more then 10 
points). The most frequent acute reaction dur-
ing radiotherapy was diarrhoea of moderate 
severity, which was well controlled by diet or 
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anti-diarrhoeal medication (it appeared in 5%, 
21.6% and 65.5% of the patients from groups 
A-C). No patient developed severe radiation 
dermatitis. No patient required treatment in-
terruption. Detailed information about toxic-
ity of treatment in patients with prophylactic 
liver irradiation has been described elsewhere 
(16). Acute postoperative morbidity was char-
acterized by wound-healing delay. The median 
wound healing time in those who underwent 
abdomino-perineal resections was 6, 6 and 4 
weeks. There was, however, no statistical dif-
ference in incidence of perineal wound infec-
tions (20.0% vs. 15.0% vs. 16.4%, groups A-C 
respectively). Anastomotic leakage appeared 
in less than 2% of all cases. Spastic ileus ap-
peared in the perioperative period in 2 (3.8%) 
patients from group A (one of them had to be 
reoperated on). Adding prophylactic liver ir-
radiation to preoperative radiotherapy in the 
group with accelerated hyperfractionation did 
not increase the incidence of acute toxic ef-
Characteristics
Fractionation (groups)
Group A
25 Gy,
5.0 Gy/fx
Group B
30 Gy,
3.0 Gy/fx
Group C
42 Gy,
1.5 Gy/fx (2 fx /day)
Total
(N =53) (N =45) (N =70) (N =168)
Age (y)
Median
Range
62
21–76
62
37–77
62
45–79
62
21–79
Sex 
F
M
21 (39.6%)
32 (60.4%)
18 (40.0%)
27 (60.0%)
27 (38.6%)
43 (61.4%)
66 (39.6%)
102 (60.4%)
Astler-Coller c stage (stage before RT)
B
C-D
Unknown
36 (67.9%)
15 (28.3%)
2 (3.8%)
31 (68.9%)
7 (15.6%)
7 (15.6%)
46 (65.7%)
23 (32.9%)
1 (1.4%)
113 (67.3%)
45 (26.8%)
10 (5.6%)
Astler-Coller p stage (postoperative pathologic stage)
B
C-D
Unknown
28 (52.8%)
25 (47.2%)
0 (0.0%)
29 (64.4%)
15 (33.3%)
1 (2.2%)
46 (65.7%)
22 (31.4%)
2 (2.9%)
103 (61.3%)
62 (36.9%)
3 (1.8%)
Zubrod
0
1-2
40 (75.5%)
13 (24.5%)
21 (46.7%)
24 (53.3%)
29 (41.4%)
41 (58.6%)
90 (53.6%)
78 (46.4%)
Distance of tumour from anal verge 
Median
≤ 6
>6
Unknown
6 cm 
28 (52.8%) 
21 (39.6%)
4 (7.6%)
5 cm
24 (53.3%)
16 (35.6%)
5 (11.1%)
7 cm
14 (20.0%)
50 (71.4%)
6 (8.6%)
7 cm
66 (39.3%)
87 (51.8%)
15 (8.9%)
Overall treatment time (days)
Median
Range
6
5–9
14
11–21
20
18–29
14
5–29
Postoperative chemotherapy
Yes
No
26 (49.1%)
27 (50.9%)
21 (46.7%)
24 (53.3%)
28 (40.0%)
42 (60.0%)
75 (44.6%)
93 (55.4%)
Haemoglobin concentration before RT (g/dL)
Median
Range
13.0
(7.2–15.7)
13.7
(8.0–16.0)
13.3
(9.4–16.7)
13.4
(7.2–16.7)
Table 1. Characteristics of 168 patients with rectal cancer treated in the Centre of Oncology, Maria Sklodowska-Curie 
Memorial Institute – Gliwice
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fects and did not affect the rates of adherence 
to postoperative chemotherapy. There was no 
death from toxic effects.
Loco-regional control
The loco-regional control rate at fi ve years was 
81% in the study population of 168 patients. 
In the univariate analyses, treatment group 
assignment (p=0.016) (Fig. 1), haemoglobin 
concentration before radiotherapy (p= 0.012) 
and postoperative chemotherapy (p=0.01) 
were signifi cant predictors of the risk of loco-
regional recurrence. Patients who had postop-
erative chemotherapy were at higher risk for 
recurrence, which can be attributed to selec-
tion criteria for this therapy. Age, sex, stage 
of disease, location of tumour (distance of the 
tumour from the anal verge), performance 
status and type of operation did not appear 
to signifi cantly infl uence LRC (Table 3). In a 
multivariate Cox regression analysis haemo-
globin concentration before radiotherapy (p= 
0.009) and fractionation scheme (p=0.008) ap-
peared as independent predictors of the risk 
of loco-regional recurrence, whereas adjuvant 
chemotherapy had no independent prognostic 
value with respect to this endpoint (p>0.05).
Metastases-free survival
In the present study, the 5-year cumulative 
incidence of distant metastases was 34.0% for 
patients in group A, 32% and 35% in groups 
B and C respectively. The most common sites 
of metastases were the liver (17.3%) and lungs 
(16.7%). Interestingly, in the subgroup of pa-
tients with prophylactic liver irradiation none 
Characteristics Fractionation (groups)
Group A
25 Gy,
5.0 Gy/fx
Group B
30 Gy,
3.0 Gy/fx
Group C
42 Gy,
1.5 Gy/fx (2 fx /day)
Total
Type of resection
Anterior
Abdominoperineal
Hartmann’s 
22 (41.5%)
27 (50.9%)
4 (7.5%)
23 (51.1%)
21 (46.7%)
1 (2.2%)
43 (61.4%)
25 (35.7%)
2 (2.9 %)
88 (52.4%)
73 (43.5%)
7 (4.2%)
Surgery-radiotherapy interval (days)
Median
Range
3
1–20
9
1–33
6
2–30
6
1–33
Table 2. Characteristics of the type of resection and radiotherapy-surgery interval in 168 patients treated with preoperative 
radiotherapy
Fig. 1. Loco-regional control according to fractionation schedule. 
The difference in outcomes is statistically signifi cant
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p= 0.016
of the patients had liver metastases. The frac-
tionation scheme did not infl uence metastases-
free survival (Fig. 2). Other variables such as 
age, sex, clinical stage of disease, distance of 
the tumour from the anal verge, performance 
status and type of operation also did not sig-
nifi cantly infl uence MFS (Table 3). However, 
in a univariate analysis it was signifi cantly in-
fl uenced by postoperative pathological stage 
and adjuvant chemotherapy. In patients who 
received chemotherapy this can be attributed 
to selection criteria for this therapy, since it 
was given only to patients with Astler-Coller 
stage C.
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Overall survival
The median follow-up for surviving patients 
was 5.2 years (95% confi dence interval 4.95-
5.62). The 5-year overall survival rate was 
64%, 59% and 74% in groups A, B, C respec-
tively (p=0.056). The overall survival time ac-
cording to the fractionation scheme is shown 
in Figure 3. In the univariate analyses postop-
erative pathological stage (p=0.006), distance 
of the tumour from the anal verge (p= 0.015) 
and postoperative chemotherapy (p=0.047) 
signifi cantly infl uenced OS. By contrast, frac-
tionation scheme, age, sex, clinical stage of 
disease, performance status, haemoglobin 
concentration before the treatment and type 
of operation did not signifi cantly infl uence OS 
(Table 3). A multivariate Cox regression mod-
el revealed that tumour location had an inde-
pendent and signifi cant infl uence on survival 
(p=0.04).
Late reactions
Among the patients in whom sphincter-sparing 
surgery was performed, 19.3% reported some 
form of faecal incontinence; 1 patient from 
group A required persistent use of pads for 
this complication. The incidence of perineal-
vaginal fi stulas in the whole group of women 
Characteristics 5-year
LRC
p 5-year
MFS
p 5-year
OS
p
Fractionation scheme
A
B
C
80
69
90 0.016
66
61
62 0.8
64
59
74 0.056
Age (y)
≤ 62
>62
84
77 0.74
66
60 0.66
73
60 0.14
Sex 
F
M
79
83 0.42
64
63 0.9
63
68 0.78
Astler-Coller c stage(stage before RT)
B
C-D
85
72 0.11
67
58 0.94
69
65 0.82
Astler-Coller p stage(postoperative pathologic stage)
B
C-D
85
72 0.07
73
51 0.0004
75
54 0.006
Zubrod
0
1-2
79
84 0.71
66
62 0.19
70
60 0.24
Distance of tumour from anal vergeMedian
≤ 6
>6
77
86 0.16
67
66 0.73
59
75 0.015
Postoperative chemotherapy
Yes
No
74
90 0.01
47
81 0.0006
59
76 0.047
Haemoglobin concentration before RT (g/dL)
≤ 13
>13
67
91 0.012
55
73 0.13
60
75 0.085
Type of resection
Anterior
Abdominoperineal
Hartmann’s 
86
76
62 0.1
65
62
38 0.2
71
64
69
0.3
Table 3. Prognostic factors infl uencing actuarial rates of local recurrence, distant metastases and overall survival
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with sphincter sparing surgery was 5.3%. In 
those who underwent abdomino-perineal re-
sections, a delay in healing of the wound lon-
ger than three months was observed in 14.8%, 
13.7% and 7.4% of patients from groups A-C 
respectively. Detailed information about fre-
quency of late effects in each group (incidence 
of faecal incontinence, diarrhoea, constipa-
tion and perineal-vaginal fi stulas) is shown in 
Table 4. One year after treatment two patients 
from group A underwent unsuccessful recon-
struction of the digestive tract complicated by 
necrosis of the small bowel in the region of the 
anastomosis. However, there was no signifi -
cant difference in the incidence of late effects 
among the three treatment groups.
DISCUSSION
Radiation morbidity is as important as tu-
mour control when determining the value of 
a given fractionation schedule. Thus, in this 
study, we evaluated the effi cacy and toxicity 
of three different fractionation schedules of 
preoperative radiotherapy in patients with 
resectable rectal cancer. In general, all three 
schedules of preoperative radiotherapy were 
well tolerated. There was higher incidence of 
mild/severe diarrhoea during radiotherapy in 
schedule C compared to A and B. This can be 
explained by the duration of radiation thera-
py, which was shorter in schedules A and B 
than the usual time required for appearance 
of clinical symptoms related to acute reaction. 
In schedule C the overall duration of radiation 
therapy (about 3 weeks) was long enough for 
symptoms to become clinically apparent. By 
Fig. 2. Metastases-free survival according to fractionation 
scheme. The difference in outcomes is not statistically 
signifi cant
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Characteristics Fractionation (groups)
Group A
25 Gy,
5.0 Gy/fx
Group B
30 Gy,
3.0 Gy/fx
Group C
42 Gy,
1.5 Gy/fx (2 fx /day)
Incidence of faecal incontinencea 9.1% 5.9% 8.6%
Perineal-vaginal fi stulasb 4.8% 5.9% 5.3%
Large healing delayc 14.8% 13.7% 7.4%
Diarrhoea 5.9% 5.0% 10.2%
Constipation 2.0% 0.0% 6.8%
a Analysis included only patients in whom sphincter-sparing surgery was performed.
b Analysis included only women in whom sphincter-sparing surgery was performed.
c Delay in healing of the wound longer than three months among patients after abdomino-perineal resection.
Table 4. Incidence of late normal tissue reactions in 168 patients with rectal cancer treated with preoperative radiotherapy
Fig. 3. Overall survival time according to fractionation 
scheme. The difference in outcomes is statistically signifi cant
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contrast, the incidence of perioperative mor-
bidity and the incidence of late effects were 
slightly lower in group C compared to groups 
A and B. There was also slightly longer wound 
healing time in schedule A. This can be ex-
plained by differences in fraction doses, which 
were lower in schedule C compared to A and 
B, which could contribute to sparing of late re-
sponding tissues in schedule C.
The fractionation of preoperative radio-
therapy had a signifi cant infl uence on loco-
regional control not only in univariate but 
also in multivariate analysis. While due to the 
non-randomized character of the study the 
conclusions should be drawn with caution, the 
analysis has shown an acceptable local effec-
tiveness and tolerance of schedules A and C, 
and disappointing effectiveness of schedule B. 
The present study thus supports the data which 
suggest that the clinical effect of preoperative 
radiotherapy for rectal cancer is infl uenced not 
only by total radiation dose but also by overall 
radiation treatment time and dose per fraction. 
The presented data were used in an explorato-
ry attempt to estimate the a/b ratio for rectal 
cancer [17]. Suwinski et al. have estimated that 
the a/b ratio for rectal cancer is 5.06 Gy. The 
normalized equivalent dose (LQED 2 Gy) for 
schedules A, B, C was 35.7 Gy, 34.2 Gy and 39.0 
Gy respectively. The biological effect of the hy-
perfractionation schedule could be additionally 
affected by incomplete repair in tumour cells, 
which might happen between fractions given 
with a minimum 6-h interval (20). This may 
provide an explanation of the highest local ef-
fi ciency of schedule C.
For patients with positive postoperative 
pathological nodal stage the risk of distant me-
tastases was signifi cantly higher than in the 
group of patients with negative lymph nodes. 
In our study, the 5-year cumulative incidence 
of distant metastases was about two times that 
of local recurrences and had a signifi cant im-
pact on OS. This may indicate that eradicating 
micrometastases would be a key strategy for 
future novel therapies for rectal cancer. 
The local effect of radiotherapy was of the 
same magnitude regardless of the location of 
the tumour in the rectum. However, the sur-
vival benefi t was seen in patients in whom the 
distance of the tumour from the anal verge was 
longer than 6 cm, with negative pathological 
nodal stage. The paradoxical effect of chemo-
therapy can be attributed to selection criteria 
for this therapy. It was given only to patients 
with pathological Astler-Coller stage C. 
Several studies have emphasized that hae-
moglobin concentration is a well-recognized 
prognostic factor, which infl uences treatment 
outcome. This was also confi rmed in our study; 
haemoglobin concentration before the treat-
ment signifi cantly infl uenced loco-regional 
control. 
The non-randomized selection of patients 
for a given fractionation schedule limits the 
strengths of conclusions from the present 
study. Clearly, however, the present analysis 
suggests the necessity for further clinical re-
search in a randomized fashion to assess more 
precisely the real impact of the type of pre-
operative radiotherapy on the effect and toler-
ance of combined treatment.
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